Xian Liu

Dr. Xian Liu

health technology and informatics, The Hong Kong Polytechnic University, Hong Kong, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Chemical Engineering Journal
Verified
Journal Article
Closed access
RLRuixi Li
Ruixi Li
JGJingxuan Guo
Jingxuan Guo
YDYishan Duan
Yishan Duan
XLXian Liu
Xian Liu
LGLijuan Gui
Lijuan Gui
ZYZhenwei Yuan
Zhenwei Yuan

17 December 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YXYue Xu
Yue Xu
HLHua Li
Hua Li
SXShufen Xu
Shufen Xu
XLXian Liu
Xian Liu
JLJingjing Lin
Jingjing Lin
ZYZhenwei Yuan
Zhenwei Yuan

10 June 2022 in Chinese Chemical Letters
Verified
Journal Article
Closed access
LGLijuan Gui
Lijuan Gui
KWKaizhen Wang
Kaizhen Wang
YWYuxin Wang
Yuxin Wang
JYJun Yan
Jun Yan
XLXian Liu
Xian Liu
ZYZhenwei Yuan
Zhenwei Yuan

12 September 2023 in Analytical Chemistry
Verified
Journal Article
Closed access
JYJun Yan
Jun Yan
KWKaizhen Wang
Kaizhen Wang
LGLijuan Gui
Lijuan Gui
XLXian Liu
Xian Liu
YJYingying Ji
Yingying Ji
ZYZhenwei Yuan
Zhenwei Yuan

21 May 2021 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
XLXian Liu
Xian Liu
JCJu-Yu Chen
Ju-Yu Chen
YCYueh Chien
Yueh Chien
YYYi-Ping Yang
Yi-Ping Yang
MCMing-Teh Chen
Ming-Teh Chen
LLLiang-ting LIN
Liang-ting LIN
Glioblastoma (GBM) is one of the most devastating cancers, with an approximate median survival of only 16 months. Although some new insights into the fantastic heterogeneity of this kind of brain tumor have been revealed in recent studies, all subclasses of GBM still demonstrate highly aggressive invasion properties to the surrounding parenchyma. This behavior has become the main obstruction to current curative therapies as invasive GBM cells migrate away from these foci after surgical therapies. Therefore, this review aimed to provide a relatively comprehensive study of GBM invasion mechanisms, which contains an intricate network of interactions and signaling pathways with the extracellular matrix (ECM). Among these related molecules, TGF-β, the ECM, Akt, and microRNAs are most significant in terms of cellular procedures related to GBM motility and invasion. Moreover, we also review data indicating that Musashi-1 (MSI1), a neural RNA-binding protein (RBP), regulates GBM motility and invasion, maintains stem cell populations in GBM, and promotes drug-resistant GBM phenotypes by stimulating necessary oncogenic signaling pathways through binding and regulating mRNA stability. Importantly, these necessary oncogenic signaling pathways have a close connection with TGF-β, ECM, and Akt. Thus, it appears promising to find MSI-specific inhibitors or RNA interference-based treatments to prevent the actions of these molecules despite using RBPs, which are known as hard therapeutic targets. In summary, this review aims to provide a better understanding of these signaling pathways to help in developing novel therapeutic approaches with better outcomes in preclinical studies.

Verified
Journal Article
Open access
PDF file
PTPok Kong Tsoi
Pok Kong Tsoi
XLXian Liu
Xian Liu
MWMan Ding Wong
Man Ding Wong
LLLiang-ting LIN
Liang-ting LIN
Glioblastoma (GBM) is a highly aggressive brain tumour characterised by a poor prognosis and resistance to anti-angiogenic treatments. Vasculogenic mimicry (VM), in which tumour cells form vessel-like structures independent of endothelial cells, has emerged as a key mechanism hindering the efficacy of anti-angiogenic therapies. Recent research highlights the central role of RNA-binding proteins (RBPs) in regulating VM through diverse post-transcriptional mechanisms, including mRNA decay induction and translational repression. Several oncogenic RBPs, such as HuR and HNRNPs, promote VM and tumour aggressiveness, while others, including RBMS3, act as suppressors of VM. Despite the prominent oncogenic roles of multiple RBPs, RBP-targeting compounds aimed at suppressing VM in GBM have remained at an early stage due to a number of limitations. This review summarises the role of VM in the treatment resistance of GBM, RBP regulation of VM, and the current landscape and future direction of RBP-targeted therapies aimed at overcoming VM-mediated treatment resistance in GBM.